ClinicalTrials.gg
CompletedNCT00960557OXi4503Updated Aug 23, 2011

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden

A Phase 1 interventional study of Combretastatin A1 Diphosphate (OXi4503) in Neoplasm Metastasis, sponsored by Mateon Therapeutics. Completed at 4 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-23.

Sponsored by Mateon Therapeutics · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Neoplasm Metastasis with a site in Australia — 60 open to participants now, 106 under way, 34 of them phase 3. Neoplasm Metastasis · Australia.

Enrollment
246th of 253
16 · median 227
Started
2009
with 7 others
Phase 1
67 of 260
20 open now
Registered
46th of 260
by date

Among the 260 studies in Neoplasm Metastasis with a site in Australia, this one is the 246th largest by enrollment of the 253 interventional ones that give a count, is one of 8 that started in 2009, is one of 67 in phase 1, and was the 46th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

60 of the 260 studies in Neoplasm Metastasis with a site in Australia are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Neoplasm Metastasis with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.

03

Conditions studied

  • Neoplasm Metastasis

Keywords

  • hepatic tumor burden
  • liver cancer
  • liver carcinoma
  • carcinoma
  • hepatic cancer
  • hepatic carcinoma
  • VDA
  • Vascular Disrupting Agent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed carcinoma. Tumor must be to standard therapies, or have no acceptable standard therapy.
  2. by criteria.
  3. Subjects must be at least 28 days from other therapy and at least 2 weeks after chemotherapy or radiation therapy.
  4. Age 18 years or older.
  5. (ECOG) Performance Score of less than 1.
  6. of greater than 12 weeks.
  7. greater than 10 g/dL.
  8. Adequate hepatic function.
  9. Adequate renal function.
  10. Adequate bone marrow reserve.
  11. Able to maintain potassium, calcium and magnesium levels within normal ranges.
  12. Must be able to provide written .
  13. All women of (WOCBP) must have a negative serum pregnancy test.
  14. WOCBP and fertile men and their partners must agree to use an effective form of during the study and for 90 days after the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled .
  2. No other active .
  3. Poorly controlled hypertension.
  4. Recent history of serious cardiovascular conditions.
  5. Recent history of CVA, , or intermittent claudication.
  6. Current anticoagulation therapy.
  7. History of cardiac arrhythmias.
  8. Abnormal findings.
  9. Subjects who require concomitant medications which cause prolongation.
  10. Major surgery within 30 days of treatment, or minor surgery within 7 days of treatment.
  11. Uncontrolled, active infection.
  12. Subjects who are pregnant or lactating.
  13. Subjects with any other intercurrent medical condition.
  14. Subjects with a history of solid organ transplant or bone marrow transplant.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Combretastatin A1 Diphosphate

    Drug: Combretastatin A1 Diphosphate (OXi4503)

Interventions

  • DrugOxi 4503Studies of Oxi 4503Oxi 4503 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. To determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.

    Time frame: 6 Months

Secondary outcomes

  1. To determine progression-free survival (PFS).

    Time frame: 6 Months

07

Study locations

4 sites
  • OXiGENE Investigational Site
    Westmead, New South Wales 2145, Australia
  • OXiGENE Investigational Site
    South Brisbane, Queensland 4101, Australia
  • OXiGENE Investigational Site
    Adelaide, South Australia 5000, Australia
  • OXiGENE Investigational Site
    Bentleigh, Victoria 3165, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2009
First posted
Aug 18, 2009
Start
Jul 2009
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Last update
Aug 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00960557
Lead sponsor
Mateon Therapeutics
Responsible party
Sponsor
First posted
Aug 18, 2009
Start date
Jul 2009
Primary completion
Oct 2010
Completion
Oct 2010
Last update
Aug 23, 2011

Study contacts

Michael Brown, MD
principal investigator · Royal Adelaide Hospital
Jason Lickliter, MD
principal investigator · Monash Medical Centre
Paul Mainwaring, MD
principal investigator · Mater Adult Hospital
Michael Millward, MD
principal investigator · Sir Charles Gairdner Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxi 4503

Start the discussion